This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
13 September 2016
In the version of this article initially published, Rob Lenz's quote should have said that about half of patients who discontinue using a prophylactic drug for migraines do so within the first month, rather than within the first week. The error has been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sinha, G. Migraine mAbs crowd into late-stage trials. Nat Biotechnol 33, 676–677 (2015). https://doi.org/10.1038/nbt0715-676c
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0715-676c